Development of Direct Thrombin Inhibitors in Comparison with Glycosaminoglycans

ABSTRACT

The progress in molecular biology has stimulated interest in the structure and function of thrombin. It has improved the understanding of its central role in thrombogenesis and has clarified the molecular events of inhibitor binding. This development has resulted in the production of recombinant hirudins and the design of hirudin analogues. It has also allowed the molecular design of synthetic antithrombins and encouraged the development of these products for clinical use. All pharmacological aspects speak in favor of the use of the direct thrombin inhibitors as antithrombotic agents, especially in the potential indications in which thrombin plays a crucial role in the pathogenesis. If their apparent advantages in comparison to glycosaminoglycans can be shown effectively, the direct thrombin inhibitors may become the drug of choice for certain indications.

KEYWORD

Thrombin inhibitors - glycosaminoglycans - hirudin - heparin - effects - clinical use

REFERENCES

• 1 Markwardt F. Blutgerinnungshemmende Wirkstoffe aus blutsaugenden Tieren.  Jena: Gustav Fischer; 1963
• 2 Markwardt F, Landmann H. Blutgerinnungshemmende Proteine, Peptide und Aminosäurederivate. In: Markwardt F, ed. Handbuch der experimentellen Pharmakologie, Bd 27: Anticoagulantien. New York: Springer 1971: 76-142
• 3 Markwardt F. Coagulation inhibitors of blood-sucking animals-A new line of developing antithrombotic drugs.  Pharmazie . 1993;  49 313-316
• 4 Markwardt F. Antithrombotic agents from hematophagous animals.  Clin Appl Thromb Hemost . 1996;  2 75-82
• 5 Markwardt F. Isolierung und chemische Charakterisierung des Hirudins.  Hoppe Seylers Z Physiol Chem . 1957;  308 147-156
• 6 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombin-Inhibitors Hirudin.  Hoppe Seylers Z Physiol Chem . 1967;  348 1381-1386
• 7 Markwardt F. Hirudin as an inhibitor of thrombin. In: Colowick SP, Kaplan NO, eds. Methods in Enzymology Vol. XIX, Proteolytic Enzymes. New York: Academic Press 1970: 924-932
• 8 Markwardt F. Development of hirudin as an antithrombotic agent.  Semin Thromb Hemost . 1989;  15 269-282
• 9 Markwardt F. Hirudin and derivatives as anticoagulant agents.  Thromb Haemost . 1991;  66 141-152
• 10 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent.  Biomed Biochim Acta . 1985;  44 1007-1013
• 11 Markwardt F. Le genie genetique conduit au retour de l'hirudine comme anticoagulant.  Sang Thromb Vaisseaux . 1991;  3 519-522
• 12 Markwardt F. The development of hirudin as an antithrombotic drug. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus 1997: 145-160
• 13 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.  Thromb Haemost . 1982;  47 226-229
• 14 Markwardt F, Fink E, Kaiser B. Pharmacological survey of recombinant hirudin.  Pharmazie . 1988;  43 202-207
• 15 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin.  Thromb Res . 1989;  54 377-388
• 16 Markwardt F. Synthetic, low molecular weight thrombin inhibitors. A new concept of anticoagulants?.  Haemostasis . 1974;  3 185-202
• 17 Markwardt F. Pharmacological control of blood coagulation by synthetic, low-molecular-weight inhibitors of clotting enzymes. A new concept of anticoagulants.  Trends Pharmacol Sci . 1980;  1 153-157
• 18 Markwardt F. Pharmacologic control of blood coagulation by synthetic, low molecular weight inhibitors of clotting enzymes.  Ann NY Acad Sci . 1981;  370 757-764
• 19 Markwardt F. Development of synthetic proteinase inhibitors as anticoagulant agents. In: Harenberg D, Heene L, Stehle G, Schettler G, eds. New Trends in Haemostasis, Coagulation Proteins, Endothelium and Tissue Factors NewYork: Springer 1990: 177-187
• 20 Hauptmann J, Markwardt F. Pharmacological aspects of the development of selective synthetic thrombin inhibitors as anticoagulants.  Semin Thromb Hemost . 1992;  18 200-217
• 21 Markwardt F, Klöcking H P. Antithrombotic effect of synthetic thrombin inhibitors.  Thromb Res . 1972;  1 243-252
• 22 Markwardt F, Nowak G, Stürzebecher J, Griessbach U, Walsmann P. Clinico-pharmacological studies with recombinant hirudin.  Thromb Res . 1988;  52 393-400
• 23 Markwardt F, Nowak G, Stürzebecher J. Clinical pharmacology of recombinant hirudin.  Haemostasis . 1991;  21 133-136
• 24 Eschenfelder V. Pharmacologic considerations in the development of hirudin and its derivatives for cardiovascular indications. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus Inc. 1997: 161-174
• 25 Richter M, Walsmann P, Markwardt F. Plasma level of dextran-r-hirudin.  Pharmazie . 1989;  44 73-74
• 26 Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behavior.  Biomed Biochim Acta . 1990;  49 1103-1126
• 27 Hauptmann J, Kaiser B, Markwardt F. Anticoagulant action of synthetic tight binding inhibitors of thrombin in vitro and in vivo.  Thromb Res . 1985;  39 711-715
• 28 Hauptmann J, Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside.  Thromb Res . 1999;  93 203-241
• 29 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors.  Thromb Res . 1986;  43 613-620
• 30 Hauptmann J, Brüggener E, Markwardt F. Effect of heparin, hirudin and a synthetic thrombin inhibitor on antithrombin III in thrombin induced disseminated intravascular coagulation in rats.  Haemostasis . 1987;  17 321-328
• 31 Markwardt F. Hirudin: the promising antithrombotic.  Cardiovasc Drug Rev . 1992;  10 211-232
• 32 Erikson B I, Wille-Jørgenson P, Kälebo P. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
• 33 Markwardt F. Pharmacology of selective thrombin inhibitors.  Nouv Rev Fr Hematol . 1988;  30 161-165